Results 171 to 180 of about 294,551 (284)

Downregulation of sST2, a decoy receptor for interleukin‐33, enhances subcutaneous tumor growth in murine pancreatic cancer cells

open access: yesFEBS Open Bio, EarlyView.
Subcutaneous implantation of murine Panc02 pancreatic cancer cells depleted of sST2, a soluble decoy receptor for the proinflammatory interleukin‐33 (IL‐33), leads to a decreased number of GLUT4‐positive cancer‐associated adipocytes, reduced levels of the anti‐inflammatory molecule adiponectin, increased phosphorylation of IκBα, elevated Cxcl3 ...
Miho Akimoto   +5 more
wiley   +1 more source

Stromagenesis and cancer‐associated fibroblast heterogeneity in primary tumors and metastasis: focus in non‐small cell lung cancer

open access: yesFEBS Open Bio, EarlyView.
Cancer‐associated fibroblasts (CAFs) play different roles in NSCLC progression and metastasis. Their heterogeneous origins and phenotypes shape the tumor microenvironment and influence metastatic spread. This review highlights NSCLC CAF subtypes, their potential cellular sources, and their differential distribution across primary tumors and distant ...
Alejandro Bernardo   +3 more
wiley   +1 more source

PERSPECTIVES AND PHYTOTHERAPEUTIC APPROACHES IN BREAST NEOPLASMS: A SCOPE REVIEW

open access: bronze, 2023
Paloma Horrana Almeida Silva   +4 more
openalex   +2 more sources

A unified model for Duchenne muscular dystrophy gene involvement in cancer: context‐dependent tumour suppression and oncogenicity

open access: yesFEBS Open Bio, EarlyView.
We propose a context‐dependent model where the Duchenne muscular dystrophy (DMD) gene acts as a tumour suppressor in aggressive tumours and as an oncogene in less aggressive ones. We propose this model as a unified framework to explain the opposing survival associations with DMD expression and to guide experimental exploration of the dual role of DMD ...
Lee Machado   +4 more
wiley   +1 more source

Breast neoplasm with distinct histological subtypes: A case report

open access: bronze, 2023
Rosana Zabulon Feijó Belluco   +7 more
openalex   +1 more source

Report on the 2nd MObility for Vesicle research in Europe (MOVE) symposium—2024

open access: yesFEBS Open Bio, EarlyView.
The 2nd MObility for Vesicle research in Europe (MOVE) Symposium in Belgrade brought over 280 attendees from 28 countries to advance extracellular vesicle (EV) research. Featuring keynotes, presentations, and industry sessions, it covered EV biogenesis, biomarkers, therapies, and manufacturing.
Dorival Mendes Rodrigues‐Junior   +5 more
wiley   +1 more source

Glial Fibrillary Acidic Protein Astrocytopathy Based on a Two‐Center Chinese Cohort Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Glial fibrillary acidic protein astrocytopathy (GFAP‐A) is a recently defined nosological form belonging to the class of autoimmune inflammatory disorders affecting the central nervous system (CNS). Here, we report the clinical and MRI characteristics, treatment, and prognosis of a GFAP‐A cohort from two centers in China.
Ti Wu   +13 more
wiley   +1 more source

Cognitive Resilience in Apolipoprotein ε4 Carrier Women Predicted by Neuron‐Derived Extracellular Vesicles

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The Apolipoprotein (APOE) ε4 allele is the strongest genetic risk factor for late‐onset Alzheimer's disease (AD); however, many ε4 carriers remain cognitively intact into old age. Leveraging plasma neuron‐derived extracellular vesicles (NDEVs), we sought to identify biomarkers of cognitive resilience and their interplay with APOE ...
Apostolos Manolopoulos   +17 more
wiley   +1 more source

SYHA1813, A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Recurrent high‐grade gliomas have a poor prognosis and limited therapeutic options. This study aimed to evaluate the safety and efficacy of SYHA1813, a dual inhibitor of VEGFR and CSF1R, in patients with recurrent high‐grade gliomas.
Zhuang Kang   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy